Phase II clinical study will explore dose and safety, immunogenicity in 4 age groups, including 18-59 years old group, 6-17 years old group, 3-5 years old group, 6-35 months old group, with a total of 1716 subjects.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
the incidence and severity of any adverse reactions/events within 30 minutes after each dose of vaccination
Timeframe: through 30 minutes after each dose
the incidence and severity of adverse reactions/events within 0-7 days after each dose of vaccination
Timeframe: through 7 days after each dose
the incidence and severity of non-collective adverse reactions/events within 30 days after each dose of vaccination
Timeframe: through 30 days after each dose
the incidence of SAE from the first dose of vaccination to 6 months after the full course of vaccination
Timeframe: up to 6 months after the full course of vaccination
Antibody titer of HBGA-blocking antibody on the 14th day after the full course of vaccination
Timeframe: 14th day after the full course of vaccination
4-fold Seroconversion rate on the 14th day after the full course of vaccination
Timeframe: 14th day after the full course of vaccination
Antibody titer of（NoV GI.1 and GII.4 HBGA-blocking antibody）on the 14th day after the full course of vaccination
Timeframe: 14th day after the full course of vaccination